Meet Thoracic Surgeon David Jones
David R. Jones, MD
Chief, Thoracic Service, Department of Surgery; Co-Director, Druckenmiller Center for Lung Cancer Research; Fiona and Stanley Druckenmiller Chair in Lung Cancer; Executive Vice-Chair, Department of Surgery
Lung and Esophageal Cancers; Thymic Malignancies; Pulmonary Metastases; Germ Cell Tumors, Mediastinal Tumors, Tumors of the Trachea and Bronchus, Minimally Invasive Surgery; Video-Assisted Thoracic Surgery (VATS); endobronchial ultrasound (EBUS)
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Jones accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
In New York State
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York HMO, EPO, PPO, and POS plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Memorial Sloan Kettering is not an in-network provider for Empire's Medicare Managed Care plan known as Mediblue). However, effective 1/1/22, most of Empire's BCBS Medicare Advantage plans, including the NYC retiree Plus plan, will be in-network with MSK. Please call Empire BCBS to confirm if you specific plan is in-network.
- Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
In New Jersey
Memorial Sloan Kettering is an in-network provider with some Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. For example, the PPO plan is in-network with our Manhattan locations.
Horizon Blue Cross HMO is only in-network with our Basking Ridge, Bergen and Monmouth locations. It does not allow access to our Manhattan facilities.
Horizon Blue Cross PPO is in network with our Basking Ridge, Bergen, Monmouth and Manhattan locations.
OMNIA Plans: Tier I EPO based plan policy is only in-network with our Basking Ridge, Bergen and Monmouth locations and does not allow access to our Manhattan sites. Tier II EPO is only in-network with our Manhattan sites if it is a blue-card plan (there would be a suitcase logo indicating PPO on the front of the card).
Other plans may only be in-network at our Basking Ridge, Bergen or Monmouth locations.
Outside New York State and New Jersey
Some, but not all, Blue Cross Blue Shield plans outside of New York and New Jersey include Memorial Sloan Kettering as an in-network provider. Contact your insurance to find out if your plan provides in-network access to Memorial Sloan Kettering.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans and Medicare plans. Emblem Health does not include us in any of its Select Care network plans or in their Medicare Bold and Reserved Networks plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
In New York: Memorial Sloan Kettering’s New York locations are in-network with the Emblem
In New Jersey: Memorial Sloan Kettering’s New Jersey locations in Basking Ridge, Bergen and Monmouth are in-network with the Horizon Medicare Advantage Plan. This plan is not accepted for care provided at MSK’s New York locations.
If you are enrolled in any other Medicare Advantage plan, please contact your insurance carrier to determine your benefits and coverage at Memorial Sloan Kettering since your access may be limited.
Memorial Sloan Kettering is not an in-network provider in Emblem’s Medicare Bold or Reserved Network plans. However, effective 4/1/22, most of the Empire BCBS Medicare Advantage plans, including the NYC retiree Plus plan, will be in-network with MSK. Please call Empire BCBS to confirm if your specific plan is in-network.
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, West Virginia University
General Surgery - West Virginia University; Thoracic Surgery - University of North Carolina
Molecular Oncology - University of North Carolina
General Surgery; Thoracic Surgery
As a thoracic surgeon for more than 23 years, I have devoted my clinical practice to diagnosing and treating patients with lung cancer, esophageal cancer, tumors of the mediastinum (thymus gland and germ cell tumors), and tumors that have metastasized (spread) to the lung from other parts of the body. In addition to serving as Chief of Thoracic Surgery, I am the Co-Director of the Druckenmiller Center for Lung Cancer Research at Memorial Sloan Kettering Cancer Center.
I am committed to enhancing the quality of care and the outcomes for all patients who receive thoracic surgery at MSK. I frequently meet with patients who request second or third opinions regarding the best treatment options for their disease.
Each year, I see approximately 1,350 patients and perform more than 350 operations. The vast majority of the lung cancer surgeries and esophageal cancer resections I perform are done using minimally invasive approaches, such as video-assisted thoracic surgery (VATS). These enable the surgeon to make smaller and fewer incisions during the operation and often result in patients having less pain and a faster recovery. I was one of the first thoracic surgeons in the United States to develop expertise in these techniques.
I am also involved in multiple national and international clinical trials examining the role of surgery combined with immunotherapy and targeted therapies for people with operable lung and esophageal cancers.
Being diagnosed with cancer is an overwhelming life event. When patients and caregivers meet with me, I hope they leave with a sense of hope about their future. I want them to know that I, together with a whole team of cancer experts, will do our best to take good care of them.
Most patients are concerned about how cancer may impact their life expectancy as well as how the disease and related treatments will affect their quality of life. I take the time to tailor a treatment plan that maximizes the opportunity to cure a person’s cancer while minimizing the potential complications and side effects of surgery, such as pain, infection, or reduced lung function. When appropriate, the plan may also include the opportunity to participate in a clinical trial.
I became interested in thoracic surgical oncology during my residency when I was in the research laboratory studying how lung and esophageal cancers develop into aggressive tumors. Today, my research focuses on the molecular mechanisms that lead to cancer metastases in people with early-stage lung and esophageal cancers. We are identifying the genetics of tumor tissue and blood to guide therapy, provide risk assessment for recurrence of disease, and better understand the biology of these cancers. In addition, our group has been a pioneer in studying the effects of certain treatments before surgery, such as immunotherapy and other therapies that target the molecules involved in cancer growth.
Outside of work, I enjoy traveling, reading books, fine wine, and spending time with friends and family. I have two amazing daughters and a wife who enjoy travel as much as I do. We have been to many places in Asia and Europe but are always planning the next trip.
Awards and Honors
- National Cancer Institute, Board of Scientific Counselors (2019-2024)
- Secretary, American Association for Thoracic Surgery (2017-2022)
- President, Southern Thoracic Surgical Association (2016-2017)
- Chair, Tumor Progression Metastasis Study Section, National Cancer Institute (2014-2016)
- West Virginia University School of Medicine Distinguished Alumnus (2013)
- Castle Connolly: America’s Top Doctors for Cancer (2006-present)
- American Association for Cancer Research Career Development Award for Translational Lung Cancer Research (2001)
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
- Clinical Trials Investigated by Dr. Jones
- Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
- Clinical Trials Co-Investigated by Dr. Jones
- A Phase I Study of CAR T-Cell Immunotherapy for Pleural Mesothelioma
- A Phase III Study of Presurgical Osimertinib Alone or with Chemotherapy versus Chemotherapy Alone for Patients with EGFR Mutation-Positive Operable Non-Small Cell Lung Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Kiankhooy A, Taylor MD, LaPar D, Isbell JM, Kozower BD, Lau CL, Jones DR. Predictors of early recurrence for node-negative T1-T2b non-small cell lung cancer. Ann Thorac Surgery 2014;98(4):1175-83.
Liu Y, Amin EB, Mayo MW, Chudgar NP, Bucciarelli PR, Kadota K, Adusumilli PS, Jones DR. CK2α’ drives lung cancer metastasis by targeting BRMS1 nuclear export and degradation. Cancer Res 2016;76:2675-86.
Chudgar NP, Brennan MF, Munhoz RR, Bucciarelli PR, Tan KS, D’Angelo SP, Bains MS, Bott M, Huang J, Park BP, Rusch VR, Adusumilli PS, Jones DR. Pulmonary metastasectomy with curative intent for soft tissue sarcoma. J Thorac Cardiovasc Surg 2017;154:319-30.
Jones DR. Bending the curve: the importance of expertise. Ann Thorac Surg 2018;103:1287-93.
Brandt WS, Yan W, Tan KS, Bains MS, Park BJ, Adusumilli PS, Huang J, Bott MJ, Rusch VW, Molena D, Isbell JM, Sihag S, Chaft JE, Kris MG, Jones DR. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis. J Thorac Cardiovasc Surg 2019;157(2):743-753.
Brandt W, Bouadallah I, Tan KS, Park BJ, Adusumilli PS, Molena D, Bains MS, Huang J, Isbell JM, Bott M, Jones DR. Predictors of distant recurrence following R0 lobectomy for pN0 lung adenocarcinoma. J Thorac Cardiovasc Surg 2018;155:1212-24.
Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Yang SC, Jones DR, Broderick SR, Battafarano R, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Caushi J, Chan HY, Scharpf RB, White J, Gabrielson E, Zahurak M, Rosner G, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018;378:1976-86.
Caso R, Jones GD, Bains MS, Hsu M, Tan KS, Feldman DR, Funt SA, Reuter VE, Gaetano Rocco G, Jones DR. Outcomes following multidisciplinary management of primary mediastinal germ cell tumors. Ann Surg 2021 (online ahead of print).
Caso R, Jones GD, Tan KS, Bosl GJ, Funt SA, Sheinfeld J, Reuter VE, Amar D, Fischer G, Molena D, Rocco G, Bains MS, Feldman DR, Jones DR. Thoracic metastasectomy in germ cell tumor patients treated with first-line versus salvage therapy. Ann Thorac Surg 2021;111(4):1141-1149.
Caso R, Sanchez-Vega F, Tan KS, Mastrogiacomo B, Zhou J, Jones GD, Nguyen B, Schultz N, Connolly JG, Brandt WS, Bott MJ, Rocco G, Molena D, Isbell JM, Liu Y, Mayo MW, Adusumilli PS, Travis WD, Jones DR. The underlying tumor genomics of predominant histologic subtypes in lung adenocarcinoma. J Thorac Oncol 2020;15:1844-56.
Jones GD, Brandt WS, Shen R, Sanchez-Vega F, Tan KS, Martin A, Zhou J, Berger M, Solit DS, Rizvi H, Liu Y, Adamski A, Chaft J, Riely G, Rocco G, Bott MJ, Travis WD, Rekhtman N, Molena D, Adusumilli PS, Imielinski M, Li B, Jones DR. A genomic-pathologic annotated risk model to predict recurrence in early-stage lung adenocarcinoma. JAMA Surg 2021;156(2):e205601.
Chudgar NP, Jones DR. Thoracoscopic lobectomy after neoadjuvant tyrosine kinase inhibitor treatment. JTCVS Tech. 2021 https://doi.org/10.1016/j.xjtc.2021.02.005.
Jones DR, Wu YL, Tsuboi M, Herbst RS. Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons. J Thorac Cardiovasc Surg 2021;162:288-92.
Caso R, Connolly JG, Zhou J, Tan KS, Choi JJ, Jones GD, Mastrogiacomo B, Sanchez-Vega F, Nguyen B, Rocco G, Molena D, Sihag S, Adusumilli PS, Bott MJ, Jones DR. Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma. npj Precis Oncol 2021 (in press).
Lengel HB, Connolly JG, Jones GD, Caso R, Zhou J, Sanchez-Vega F, Mastrogiacomo B, Isbell JM, Li BT, Liu Y, Rekhtman N, Jones DR. The emerging importance of tumor genomics in operable non-small cell lung cancer. Cancers 2021 (in press).
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
David R. Jones discloses the following relationships and financial interests:
Merck & Co Inc.
Provision of Services (uncompensated)
Shanghai JoAnn Medical Technology Co., Ltd
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.